Select Session

New Strategies and Practice Advances for the Comprehensive Continuum of Gastrointestinal Neuroendocrine Tumors (NETs) What Do We Know? What Do We Still Need to Know?
Edward M. Wolin, MD - Program Chair

Real World Decision-Making for Gastrointestinal Neuroendocrine Tumors (NETs) Translating Disease Type, Progression Profiles, Biomarkers and the Safety-Efficacy Equation for Available Therapies into Optimal Clinical Management
James C. Yao, MD

Selection and Timing of Initial, Foundational Therapy for Gastrointestinal Neuroendocrine Tumors (NETs): Critical Issues for Treatment Initiation and Subsequent Management of the Complex Patient: What Does the Evidence Show? How Do the Evidence, Trials, Safety-Efficacy Profiles of SSAs and Cytotoxic Therapies and NCCN Guidelines Direct Us? When Do We Start a Therapy? When Do We Discontinue? Should Some Foundational Therapies Be Maintained Through the Natural History? How Should We Approach Anti-Proliferative vs. Cytotoxic Therapeutic Options?
Alexandria Phan, MD

Real World Therapeutics for Extending Progression-Free Survival in Patients with GI NETs—Focus on Timing, Sequencing, and Regimen Initiation and Maintenance for Antiproliferative (SSA) and Chemotherapeutic Interventions: The Evidence for Combination Approaches
Edward M. Wolin, MD - Program Chair

Novel Radiotherapeutic-Focused Strategies for Targeting Deployment of SSAs in Patients with Advanced and Metastatic GEP-NETs The Role and Rationale for Use of Technology-Focused Strategies Such as PRRT as Part of Multimodal Management Setting
Scott Paulson, MD

Clinical Case Studies and Case Management Discussions Science and Evidence into GI Oncology NET-Focused Practice: GEP-NETs Case Management Sessions—Audience Response System (ARS) Interactive Analysis of Patients NETs
Faculty Panel

Interactive Discussion and Dialogue: Case Studies on Novel Mechanisims and Advancing Therapeutic Paradigms for Optimizing Real World Management of Hypercholesterolemia
Faculty Panel